Clinical Trial News and Research

RSS

Hana Biosciences reports net loss of $5M for fourth quarter 2009

Hana Biosciences Inc., a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported financial results for the fourth quarter and year ended December 31, 2009, and provided a corporate update.

26 Mar 2010

Aastrom Biosciences' RESTORE-CLI trial: Final patient treated

Aastrom Biosciences, Inc., a leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today reported that the final patient has been treated in the company's ongoing multi-center, randomized, double-blind, placebo-controlled U.S. Phase 2b clinical trial designated RESTORE-CLI. This patient received intramuscular injections of either Aastrom's tissue repair cells (TRCs) or electrolyte solution (placebo) for the treatment of critical limb ischemia (CLI), the end-stage of peripheral arterial disease.

26 Mar 2010

Arena Pharmaceuticals initiates patient screening for phase 1 clinical trial of APD916

Arena Pharmaceuticals, Inc. announced today the initiation of patient screening in a Phase 1 clinical trial of APD916, a novel oral drug candidate discovered by Arena that targets the histamine H3 receptor for the treatment of narcolepsy and cataplexy.

25 Mar 2010

Venn Life Sciences completes $3 mn funding, acquires Dutch CRO UpToYou

Venn Life Sciences has just completed a significant funding round of over $3 million, to enable it to further accelerate the growth of its business.

25 Mar 2010

Scott & White seeks breast cancer patients for Phase II clinical trial

Scott & White Healthcare researchers are studying an investigational agent that targets metastatic breast cancer to find if it can stop cancer cells from continuing to grow.

25 Mar 2010

UCSF Study: HIV prevention services in clinical settings reduces risk behaviors

UCSF researchers have shown that delivering HIV prevention services to people living with HIV in clinical settings can sharply reduce their sexual risk behaviors.

25 Mar 2010

New ultrasound device shows promising results for treating joint and muscle pain

It's lightweight, smaller than most iPods and can deliver low-intensity ultrasound therapy for up to 10 hours. It just might revolutionize pain relief - and save patients time.

25 Mar 2010

Isotechnika Pharma releases fourth quarter financial results; reviews operational and scientific highlights for 2009

Isotechnika Pharma Inc. has released its financial results for the fourth quarter and year ended December 31, 2009 and provided a review of the Company's operational and scientific highlights for 2009

25 Mar 2010

Clinic sites seek gay men to participate in HIV vaccine study

Clinic sites in 13 cities across the U.S. are looking for a total of 1,350 HIV-negative gay men to participate in the latest HIV vaccine study from the HIV Vaccine Trials Network (HVTN). And they're using social media to help reach these individuals where they are, which, these days, is increasingly online.

25 Mar 2010

MediciNova reports net loss of $5.9 million for 2009 fourth quarter

MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced financial results for the fourth quarter and full year ended December 31, 2009.

25 Mar 2010

Alzheimer's Foundation of America applauds dementia-related provisions in health reform law

The Alzheimer's Foundation of America (AFA) is extremely pleased that the historic health reform signed into law by President Obama late this morning, after passing the U.S. House of Representatives on Sunday and the U.S. Senate in December, includes a number of provisions that are especially significant for AFA's constituents—and bode well for improving quality of life for individuals with Alzheimer's disease and related dementias, and their family caregivers. In particular, we are grateful that the final action addresses many of the practical and financial needs faced daily by this population, speaks to preventative issues and bolsters training of dementia care professionals.

25 Mar 2010

Hepatic encephalopathy drug XIFAXAN 550 mg tablets receives FDA marketing approval

Salix Pharmaceuticals, Ltd. today announced the U.S. Food and Drug Administration has granted marketing approval for XIFAXAN 550 mg tablets for reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years of age or older. HE is a serious disorder caused by chronic liver failure, resulting in cognitive, psychiatric and motor impairments. This approval was supported by findings from the largest randomized trial of maintenance therapy in HE conducted to date, which assessed the efficacy and safety of XIFAXAN 550 mg tablets and demonstrated a statistically significant and clinically meaningful reduction in the risk of overt HE recurrence.

25 Mar 2010

Cardiologist receives grant to study impact of erectile dysfunction drugs on muscular dystrophy patients

A Cedars-Sinai Heart Institute cardiologist has been awarded a three-year, nearly $1 million grant from the Muscular Dystrophy Association (MDA) to study whether drugs used to treat erectile dysfunction could also be used to improve muscle blood flow and reduce fatigue in muscular dystrophy patients.

25 Mar 2010

Xifaxan drug receives FDA approval

The U.S. Food and Drug Administration today approved the use of Xifaxan for reduction in the risk of the recurrence of overt hepatic encephalopathy (HE) in patients with advanced liver disease.

25 Mar 2010

InvestorSoup.com announces investment report featuring Oncothyreon

InvestorSoup.com announces an investment report featuring Oncothyreon Inc. (Nasdaq:ONTY). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

24 Mar 2010

Virtual biopsy probes to detect precancerous polyps to be available soon

The newest generation of "virtual biopsy" colonoscopy probes being tested at the Mayo Clinic campus in Florida demonstrate that it might soon be possible to use such a device to determine whether a colon polyp is benign and not remove it for biopsy. Currently, all colon polyps are extracted during a colonoscopy and sent to a pathologist for examination, which adds time, expense, and some surgical risk, to the procedure.

24 Mar 2010

Clinical Trial News and Research

Hana Biosciences reports net loss of $5M for fourth quarter 2009

Aastrom Biosciences' RESTORE-CLI trial: Final patient treated

Arena Pharmaceuticals initiates patient screening for phase 1 clinical trial of APD916

Venn Life Sciences completes $3 mn funding, acquires Dutch CRO UpToYou

Scott & White seeks breast cancer patients for Phase II clinical trial

UCSF Study: HIV prevention services in clinical settings reduces risk behaviors

New ultrasound device shows promising results for treating joint and muscle pain

Isotechnika Pharma releases fourth quarter financial results; reviews operational and scientific highlights for 2009

Clinic sites seek gay men to participate in HIV vaccine study

MediciNova reports net loss of $5.9 million for 2009 fourth quarter

Alzheimer's Foundation of America applauds dementia-related provisions in health reform law

Hepatic encephalopathy drug XIFAXAN 550 mg tablets receives FDA marketing approval

Cardiologist receives grant to study impact of erectile dysfunction drugs on muscular dystrophy patients

Xifaxan drug receives FDA approval

InvestorSoup.com announces investment report featuring Oncothyreon

Virtual biopsy probes to detect precancerous polyps to be available soon

New software may help improve safety among senior drivers

Nabi Biopharmaceuticals expands share repurchase program to enhance shareholder value

Renowned leaders to discuss latest findings in early-stage drug development for cancer

Children with neurofibromatosis more likely to have cardiovascular problems

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

BFEB: Advances in microplate-based assays and analysis

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery